Sony DADC BioSciences and TSMC Receive AACC Award
|
By LabMedica International staff writers Posted on 29 Jul 2014 |
The American Association for Clinical Chemistry (AACC) presented Sony DADC BioSciences and Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC; Hsinchu, Taiwan) with the AACC Industry Division Award.
The winning abstract, “Versatile Electrical Platform for Accelerated Development and Commercialization of In-Vitro Diagnostic Assays,” describes a process to integrate a novel silicon biosensor into a microfluidic chip, which has the potential to enable customers to design cost-effective, mass-fabricated Point-of-Care (POC) devices with better sensitivity and higher robustness than other available solutions.
The award is selected by a committee formed by the Chair of the AACC Industry Division, and given to research deemed to present a significant contribution to the in vitro diagnostic industry in management, regulatory affairs, or improved patient care, through a new or improved medical device.
The award-winning research combines Sony DADC BioSciences’ position in original equipment manufacturer (OEM) manufacturing of smart polymer-based consumables and TSMC’s deep expertise in silicon biosensor manufacturing. It aims to overcome a major hurdle for further development of point-of-care (POC) devices by improving material compatibility and positional alignment between silicon and plastics. Both partners have applied best-in-class silicon and plastic material-sciences to create a demonstrator for a novel hybrid design. The novelty of the silicon biosensor manufactured by TSMC is complemented by solid-state bonding of silicon to microstructured plastics developed by Sony DADC BioSciences.
Closing the gap between macro and micro interfaces allows simple and robust instrument interfaces, which serve the needs of POC environments. Both companies together will engage in discussions with diagnostic industry leaders as early adopters of the new manufacturing techniques to integrate biosensors.
Dr. Christoph Mauracher, senior vice president at Sony DADC BioSciences Sony DADC BioSciences notes, “Sony DADC BioSciences has enjoyed the cooperative development with TSMC to create a novel silicon-plastic fluidic interface which enables simple integration of microfluidic functionalities like filters, mixers, valves and pumps while ensuring a robust sample input and waste management.”
Related Links:
Sony DADC BioSciences
TSMC
The winning abstract, “Versatile Electrical Platform for Accelerated Development and Commercialization of In-Vitro Diagnostic Assays,” describes a process to integrate a novel silicon biosensor into a microfluidic chip, which has the potential to enable customers to design cost-effective, mass-fabricated Point-of-Care (POC) devices with better sensitivity and higher robustness than other available solutions.
The award is selected by a committee formed by the Chair of the AACC Industry Division, and given to research deemed to present a significant contribution to the in vitro diagnostic industry in management, regulatory affairs, or improved patient care, through a new or improved medical device.
The award-winning research combines Sony DADC BioSciences’ position in original equipment manufacturer (OEM) manufacturing of smart polymer-based consumables and TSMC’s deep expertise in silicon biosensor manufacturing. It aims to overcome a major hurdle for further development of point-of-care (POC) devices by improving material compatibility and positional alignment between silicon and plastics. Both partners have applied best-in-class silicon and plastic material-sciences to create a demonstrator for a novel hybrid design. The novelty of the silicon biosensor manufactured by TSMC is complemented by solid-state bonding of silicon to microstructured plastics developed by Sony DADC BioSciences.
Closing the gap between macro and micro interfaces allows simple and robust instrument interfaces, which serve the needs of POC environments. Both companies together will engage in discussions with diagnostic industry leaders as early adopters of the new manufacturing techniques to integrate biosensors.
Dr. Christoph Mauracher, senior vice president at Sony DADC BioSciences Sony DADC BioSciences notes, “Sony DADC BioSciences has enjoyed the cooperative development with TSMC to create a novel silicon-plastic fluidic interface which enables simple integration of microfluidic functionalities like filters, mixers, valves and pumps while ensuring a robust sample input and waste management.”
Related Links:
Sony DADC BioSciences
TSMC
Latest AACC 2014 News
- Corgenix Diagnostic Ebola Test Research Earns Abstract Award
- Atomo's Blood Test Unveiled at 2014 AACC; Takes Top Award in NY
- Roche Partners with Customers, Redefines Laboratory Value
- Abbott Showcases Innovations, Helps Labs Solve Health Care Challenges
- Oncolab Exhibits Pioneering AMAS Cancer Test at AACC
- Thermo Fisher Scientific Showcases Expanded Offering for Clinical Laboratory
- Major Advances in Medical Studies Highlighted at AACC 2014
- Wheaton Offers Unique Solutions for the Clinical Market
- Seegene Reveals New Real-Time PCR at AACC 2014
- AACC Debuts Refreshed Brand Identity
- Mobile Health, Big Data, Antimicrobial Resistance Central to 2014 Meeting
- EKF Highlights Growing Product Portfolio at AACC 2014 Meeting
Channels
Clinical Chemistry
view channel
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read more
Urine-Based Test Shows Promise for Autism Screening in Children
Autism spectrum disorder (ASD) is commonly diagnosed through behavioral assessments, which can involve long waits that delay intervention. Earlier identification is linked to better developmental outcomes,... Read moreMolecular Diagnostics
view channel
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read more
Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
Lung cancer remains the leading cause of cancer death worldwide, while heterogeneous tumor genetics continue to complicate treatment decisions. Although molecular testing is increasingly used to match... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
Tertiary lymphoid structures are emerging as important indicators of antitumor immunity, but their heterogeneity and spatial context within tumors remain difficult to capture through routine diagnostics.... Read more
AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel









